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Radiologically dense breast tissue (mammographic density) is strongly associated with risk of breast cancer, but the biological
basis for this association is unknown. In this study we have examined the association of circulating levels of hormones and
growth factors with mammographic density. A total of 382 subjects, 193 premenopausal and 189 postmenopausal, without
previous breast cancer or current hormone use, were selected in each of ﬁve categories of breast density from
mammography units. Risk factor information, anthropometric measures, and blood samples were obtained, and oestradiol,
progesterone, sex hormone binding globulin, growth hormone, insulin-like growth factor-I and its principal binding protein, and
prolactin measured. Mammograms were digitised and measured using a computer-assisted method. After adjustment for other
risk factors, we found in premenopausal women that serum insulin-like growth factor-I levels, and in postmenopausal women,
serum levels of prolactin, were both signiﬁcantly and positively associated with per cent density. Total oestradiol and
progesterone levels were unrelated to per cent density in both groups. In postmenopausal women, free oestradiol
(negatively), and sex hormone binding globulin (positively), were signiﬁcantly related to per cent density. These data show an
association between blood levels of breast mitogens and mammographic density, and suggest a biological basis for the
associated risk of breast cancer.
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Differences between individuals of the same age in the radiological
appearance of the breast reﬂect differences in tissue composition.
Epithelial and stromal tissues attenuate X-rays more than does
fat, and appear light on a mammogram, while fat appears dark
(Johns and Yaffe, 1987). Extensive areas of light appearing tissue
on a mammogram, referred to as ‘mammographic density’, have
been found to be associated with 4–6-fold differences in the risk
of breast cancer, after taking into account other known risk factors
for the disease (Boyd et al, 1998).
The biological basis for inter-individual variations in breast
tissue composition, and for the association of these variations with
risk of breast cancer is, however, unknown, although several factors
are known to inﬂuence the radiographic appearance of the breast.
Mammographic density decreases with greater parity, greater body
weight, greater age (Boyd et al, 1998), and is increased by hormone
replacement therapy (Lundstro ¨m et al, 1999), and decreased by
Tamoxifen (Atkinson et al, 1999; Brisson et al, 2000). All of these
observations suggest that variations in exposure to endogenous
hormones or growth factors may be responsible for the differences
in breast tissue composition that are reﬂected in differences in the
extent of mammographic density.
The purpose of the present study was to examine, in a cross-
sectional study design, the association between mammographic
density and blood levels of endogenous hormones and growth
factors. The hormones examined include total and free oestradiol
and progesterone, sex hormone binding globulin (SHBG), growth
hormone, insulin like growth factor-I (IGF-I), its principal binding
protein - insulin-like growth factor binding protein-3 (IGFBP-3),
and prolactin.
METHODS
General method
The general method employed was to select pre- and postmeno-
pausal women without breast cancer but with different degrees of
mammographic density, to collect information from them about
risk factors, and to measure hormones and growth factors in blood
samples obtained under standardised conditions. We determined
the total area of the breast, and the area of dense tissue on
mammography, using a previously described computer assisted
method (Byng et al, 1994).
Method of sampling and classiﬁcation of breast density
Source of subjects The goal of the sampling procedure was to
assemble premenopausal and postmenopausal women with a wide
spectrum of mammographic density. Between 1994 and 1997
subjects were identiﬁed from the mammographic units of St.
Michael’s, Women’s College and Mount Sinai Hospitals in Toron-
to. Women were referred to these units for mammographic
examination for a variety of reasons, including suspicion of breast
disease, the presence of risk factors such as a family history of
breast cancer, or for routine examination. Because per cent
mammographic density is a continuous variable, we wished to
analyse it as such, without division into arbitrary categories.
However, it was impractical to measure all mammograms in the
participating institutions. We therefore used in each hospital the
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www.bjcancer.comextent of mammographic density, expressed as a percentage of the
breast area (510%, 10525%, 25550%, 50575%, and 575%),
that was recorded by radiologists during ﬁlm reporting. We wished
to ensure that we recruited women with as wide a range of
mammographic density as possible. The number of subjects in each
of the ﬁve radiological categories of density that were actually
recruited were as follows: 510% n=101, 10525% n=62,
25550%, n=60, 50575%, n=60, and 575%, n=99.
Breast density was subsequently deﬁnitively classiﬁed as a
continuous variable by quantitative methods that are described
below. On hundred and ﬁfty-ﬁve subjects (41%) fell in the same
category according to the two methods of classiﬁcation, and 317
(83%) were within one category on both methods. (The means
of the continuous measure according to quintiles are shown in
Table 3A,B.)
Method of recruitment Subjects identiﬁed in the manner
described above were sent a letter, with an explanation of the goals
and procedures of the study, followed by a phone call, during which
their eligibility was determined. Premenopausal women were eligible
for the study if they were menstruating regularly, were not pregnant
or breastfeeding, and had not had a hysterectomy or oophorectomy.
Postmenopausal subjects were eligible if they had spontaneous
amenorrhoea for at least 12 months, or had a hysterectomy and were
aged 50 or more, or had a bilateral oopherectomay at any age. All
subjects taking any type of exogenous hormone preparation in the
previous 6 months, or who had breast augmentation or reduction,
or a previous history of breast cancer, or were under investigation
for breast cancer, were excluded.
Eighteen hundred and seventy-four recruitment letters were
mailed, and we were subsequently able to contact 1134 by tele-
phone. Of these, 526 were determined to be not eligible, and 174
stated they were not interested before their eligibility could be
determined. Of the remaining 434 who were eligible, 382 agreed
to participate in the study. Thus, 88% of subjects who were
contacted, and found to be eligible (approximately 34% of all
subjects who could be contacted), agreed to take part in the study,
and the rate of participation did not vary according to the extent
of mammographic density.
Measurements
Subjects who agreed to enter the study were then visited in their
homes by the study research assistant. These visits took place in
the morning after subjects had fasted for at least 12 h. All measure-
ments in premenopausal women were made when subjects were in
the luteal phase of the menstrual cycle (between days 20–24).
Blood was refrigerated immediately after collection, spun and
serum separated within 1–2 h of collection, and stored at
7708C until analysis. The mammogram closest to the time of
the blood draw was used, and the average time interval between
the mammogram and the blood draw was 32 weeks. The phase
of the menstrual cycle at which mammograms were obtained is,
however, not known because subjects were recruited into the
present study after the mammograms had been taken.
Epidemiological data Information about epidemiologic risk
factors for breast cancer, and other factors, was collected using a
questionnaire, developed for this purpose, that included questions
about menstrual and reproductive history, and family history of
breast and other cancer.
Anthropometric measures Each subject was weighed on a
balance scale and measured for height. Skinfold thickness in the
triceps, sub-scapular, and iliac crest areas was measured using
Lange calipers, and waist and hip circumferences were measured
with a tape measure. The research assistant who made these
measurements was trained and certiﬁed by the Department of
Athletics and Recreation, University of Toronto.
Measurement of blood samples
Serum oestradiol (in premenopausal women) and progesterone
levels were measured using radioimmunassays kits purchased from
Orion Diagnostica (Oulunsalo, Finland), and the inter-assay
performance was monitored using controls provided by the kit
manufacturer. Oestradiol in serum from postmenopausal women
was measured by Esoterix Laboratories, California, USA by radio-
immunoassay after extraction.
Serum SHBG levels were determined using an established ster-
oid-binding capacity assay using reference serum samples to
control for inter-assay performance (Hammond and La ¨hteenma ¨ki,
1983). The percentages of free oestradiol in serum samples were
estimated from a nomogram describing the relationship between
serum SHBG levels and percentages of free oestradiol measured
using the centrifugal ultraﬁltration-dialysis method in a reference
population of normal weight pre- and postmenopausal women
(Langley et al, 1985). These values were then used to calculate
the free oestradiol concentrations in serum samples from the total
oestradiol measurements.
IGF-I, IGFBP-3 and growth hormone were all measured by
Esoterix, California, USA, IGF-I and IGFBP-3 using a competitive
binding radioimmunoassay, and growth hormone with a two site
immunometric assay. Prolactin was measured by radioimmunoas-
say in the Wellesley Hospital in Toronto. The per cent
coefﬁcient of variation within assays was less than 7% for all
(except progesterone which was 8.7%), and between assays was less
than 10% for all (except progesterone which was 11.9%).
Deﬁnitive classiﬁcation of breast parenchymal pattern The
measurements that are the subject of the analyses that follow were
made using a randomly selected, craniocaudal mammographic view
of one breast from each subject.
Mammograms were digitised using a Lumisys model 85, which
provides up to 12 bit density resolution and 50 mm spatial resolu-
tion, and presented for analysis as an array of 6756925 pixels
(0.067 mm
2 per pixel). Images were analysed using a computer
assisted method (Byng et al, 1994, 1996a,b). Images from subjects
in the pre and postmenopausal groups were randomly ordered, and
thus measured without knowledge of menopausal status, or of any
of the other characteristics of the subjects.
The observer selected a threshold grey value to separate the image
of the breast from the background, and a second threshold to identify
the edges of region(s) which were representative of radiographically
dense tissue. We then calculated the histogram of pixel values within
these boundaries, and calculated the size of the projected area of the
breast in the image, and of the area of density. The percentage of
radiographic density is the area of dense tissue divided by the entire
projected area of the breast and multiplied by 100.
A subset of duplicate images were included as a check on relia-
bility. Reliability of the measurements made in the present study
was high with a test-retest correlation of at least 0.9.
Statistical analysis Data analysis was carried out using the SAS
statistical software package (Sas Institute Inc, 1989). Data were
inspected for normality before analysis and, when necessary, a
transformation was applied. The distributions of many of the
hormone measurements, and, as a consequence of our recruitment
method, of the mammographic measures, were not normal and
transformations were required. Details of the transformations used
are given in the footnotes of the tables of results. Multiple regres-
sion analysis was used to examine the association between
mammographic measurements and blood levels of hormones and
growth factors after adjustment for other variables. The residuals
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inspected for patterns to ensure that the transformations were
appropriate.
Values for growth hormone were undetectable in 128 of the 382
subjects (34%) and for purposes of analysis were assigned the value
of 0.2 ng l
71, the lower limit of sensitivity for the assay. An addi-
tional 22 observations had missing growth hormone information
(19 postmenopausal, 3 premenopausal). There was, however, no
relationship between mammographic density and whether growth
hormone could be detected.
To examine the relationships between hormones, growth factors
and mammographic measures we carried out a series of multiple
regression analyses that adjusted sequentially for other factors that
could be confounding or modifying variables. For two variables,
IGF-I and total oestrogen, their respective binding proteins,
IGFBP-3 and SHBG, are known to determine the amount of free
and biologically active growth factor or hormone, and were intro-
duced into the regression analyses before the other variables.
Among the other factors examined, that included other risk factors
for breast cancer (age, age at menarche, parity, age at ﬁrst live
birth, number of live births, and a family history of breast cancer),
measures of body size, and blood levels of other hormones or
growth factors, only age and measures of body size had a substan-
tial inﬂuence on the results. Among the measures of body size
examined, that included height, weight, body mass index, waist
and hip circumference and their ratio, and skinfold thickness
measurements, the waist measurement was the most strongly corre-
lated with mammographic density, and was the measure of body
size used in these analyses. In all of these analyses both mammo-
graphic measures, and blood levels of hormones and growth
factors, were treated as continuous variables.
RESULTS
Characteristics of subjects
Table 1 describes the pre and postmenopausal subjects studied
according to the distribution of selected risk factors for breast
cancer and anthropometric variables. There were 193 premeno-
pausal, and 189 postmenopausal subjects. The mean age was
45 years for premenopausal women, and 56 years for the post-
menopausal. The average time since menopause in
postmenopausal subjects was 7 years. About 22% of pre and
18% of postmenopausal subjects had at least one ﬁrst degree
relative with breast cancer. Mean blood levels of IGF-I, growth
hormone and prolactin were all lower in postmenopausal than
in premenopausal subjects. Mean per cent breast density and
the area of dense tissue were both lower, and the areas of
non-dense tissue and total area were greater in the postmeno-
pausal.
Sixty subjects had previously taken hormone replacement ther-
apy (HRT), stopping an average of 5 years before the date of the
mammogram. After adjustment for age, the mean per cent density
was similar in those who had previously used HRT and in those
who had not, in both premenopausal (respectively 27.3, n=13,
and 28.5, n=180) and postmenopausal subjects (respectively 24.8,
n=47, and 23.3, n=142).
Relationship between growth factors, hormones and
mammographic measures
Table 2 shows the results of sequential regression analyses of
mammographic densities against IGF-I and IGFBP-3, hormones
and SHBG. There were 187 premenopausal, and 165 postmenopau-
sal women, with complete data for all of these variables. Results are
shown for both per cent mammographic density, and for the area
of dense tissue in the mammogram, as this reﬂects the amount of
stromal and epithelial tissue in the breast.
In premenopausal women, IGF-I was signiﬁcantly associated
with per cent mammographic density before and after adjustment
for IGFBP-3, age and the waist measure. Similar associations were
seen between IGF-I and the area of dense tissue, although these
were of borderline statistical signiﬁcance after adjustment was
made for age and waist. In premenopausal women, IGF-I explained
5% of the variance in per cent density. In postmenopausal subjects,
IGF-I was signiﬁcantly associated with both mammographic
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Table 1 Selected characteristics of subjects according to menopausal status
Premenopausal Postmenopausal
n=193 n=189
Mean s.d.
a Mean s.d.
Demographic, reproductive, Age (years) 44.75 (4.6) 55.95 (4.6)
and anthropometric Age at menarche (years) 12.72 (1.5) 12.98 (1.7)
variables Age at ﬁrst child (years) 27.95 (5.8) 26.43 (5.7)
Number of live births 1.48 (1.2) 1.62 (1.5)
Parity (% parous) 69.95 N/A 73.02 N/A
First degree breast cancer relative (% yes) 21.76 N/A 17.99 N/A
BMI (kg m
72)
b 25.21 (5.8) 26.04 (6.0)
Waist (cm) 71.90 (13.1) 75.51 (14.2)
Growth factor IGF-1 (ng ml
71)
c 154.61 (35.8) 129.84 (34.4)
and hormones IGFBP-3 (mg l
71)
d 2.69 (0.5) 2.80 (0.5)
Growth hormone (mgl
71)
e 1.72 (2.7) 1.34 (2.4)
Prolactin (mgl
71) 16.51 (12.0) 9.56 (5.3)
Oestradiol (pre-pmol l
71, post-ng d
71)
f 325.40 (223.7) 1.25 (2.6)
SHBG (pmol m
71)
g 56.37 (25.6) 42.81 (22.5)
Calculated free oestradiol (%) 2.09 (0.7) 1.95 (1.2)
Progesterone (nmol l
71) 29.45 (23.0) 1.75 (1.0)
Mammographic Per cent dense 28.47 (22.6) 23.64 (20.7)
measures Dense Area (cm
2) 30.20 (25.0) 25.75 (21.9)
Non-dense area (cm
2) 101.43 (66.1) 116.62 (80.8)
Total breast area (cm
2) 131.63 (57.0) 142.37 (75.4)
aStandard deviation;
bBody mass index;
cInsulin-like growth factor, n=192 and 187 for pre and postmenopausal woemn, respectively;
dInsulin-like growth factor binding protein,
n=192 and 187 for pre and postmenopausal women, respectively;
en=190 and 170 for pre and postmenopausal women, respectively;
fn=187 for postmenopausal women;
gSex
hormone binding globulin, n=188 for postmenopausal women.
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was lost after the introduction of age and the waist measurement
into the model.
In premenopausal women only, IGFBP-3 was signiﬁcantly nega-
tively associated with per cent density and dense area before but
not after adjustment for age and waist.
Growth hormone levels, in both pre and postmenopausal
women, were signiﬁcantly and positively associated with per cent
density, where they accounted for 3–5% of the variance, but these
associations were no longer signiﬁcant in either group after adjust-
ment for age and waist. Prolactin levels were not signiﬁcantly
associated with either of the mammographic measures in premeno-
pausal subjects, but were positively and signiﬁcantly associated with
both measures in postmenopausal women, before and after adjust-
ment for age and waist. Prolactin accounted for 9% of the variance
in per cent density, and 6% of the variance in dense area, in the
postmenopausal.
Total oestradiol was not associated with either mammographic
measure in the premenopausal, but was negatively associated with
per cent density in postmenopausal women, before, but not after
adjustment for SHBG. SHBG was signiﬁcantly positively associated
with both mammographic measures in pre and postmenopausal
subjects, but remained signiﬁcant after adjustment for the waist
measure only in the postmenopausal. SHBG accounted for 25%
of the variance in per cent density in postmenopausal women,
but only 10% in the premenopausal.
Progesterone was signiﬁcantly and positively associated with per
cent density in both pre and postmenopausal women, but became
non-signiﬁcant in both groups after adjustment for age and the
waist measure. (Our intention was to obtain blood samples in
premenopausal women during the luteal phase of the menstrual
cycle and 83% of subjects had progesterone levels of 5 nmol l
71
or greater indicating that ovulation had occurred). Free oestradiol,
calculated from SHBG levels, showed negative associations with per
cent density that remained statistically signiﬁcant after adjustment
only in the postmenopausal.
The adjusted least square mean levels of the hormones and
growth factors according to quintiles of per cent density are shown
in Table 3, for those hormones that remained statistically signiﬁ-
cant after adjustment for all variables, as well as for IGFBP-3.
This table shows untransformed values and they are shown for
descriptive purposes only, to illustrate the magnitudes of the asso-
ciations found. In premenopausal women, IGF-I levels were 6%
higher, IGFBP-3 levels 1% lower, and their ratio 6% higher in ﬁfth
quintile (median per cent density=61%) compared to the ﬁrst
(median per cent density=1.5%). In postmenopausal women,
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Table 2 Sequential regression analyses of mammographic measures against growth factor and hormones*
Premenopausal women (n=193) Postmenopausal women (n=189)
g
% Dense
e Dense Area
e % Dense
e Dense Area
e
(P-value) R
2 (P-value) R
2 (P-value) R
2 (P-value) R
2
IGF-1
a (ng ml
71) n=192, 187 0.02 (0.002) 0.05 0.01 (0.05) 0.02 0.01 (0.004) 0.04 0.01 (0.02) 0.03
IGF-1+IGFBP-3
b 0.03 (50.001) 0.14 0.02 (50.001) 0.13 0.02 (0.01) 0.05 0.01 (0.05) 0.03
IGF-1+IGFBP-3+age+waist
c 0.01 (0.03) 0.54 0.01 (0.05) 0.35 0.004 (0.48) 0.46 0.005 (0.43) 0.21
IGFBP-3 (mg ml
71) n=192, 187 70.90 (0.02) 0.03 71.21 (0.001) 0.05 0.38 (0.27) 0.01 0.48 (0.15) 0.01
IGFBP-3+age+waist
c 70.02 (0.95) 0.53 70.54 (0.10) 0.33 0.14 (0.57) 0.46 0.33 (0.28) 0.21
Growth hormone
d (GH) (mgl
71) n=190, 170 0.44 (0.03) 0.03 0.25 (0.20) 0.01 0.62 (0.003) 0.05 0.38 (0.07) 0.02
GH+age+waist
c 70.02 (0.88) 0.53 70.12 (0.48) 0.33 0.10 (0.55) 0.46 0.06 (0.78) 0.19
Prolactin
d (mgl
71) 1.21 (0.35) 0.005 1.10 (0.39) 0.004 5.73 (50.001) 0.09 4.60 (0.001) 0.06
Prolactin+age+waist
c 0.72 (0.42) 0.53 0.68 (0.005) 0.33 2.90 (0.01) 0.48 2.90 (0.03) 0.22
Oestradiol (pre- pmol l
71; post
d ng dl
71) n=193, 187 70.0004 (0.58) 0.002 70.001 (0.45) 0.003 71.01 (0.005) 0.04 70.67 (0.06) 0.02
k
Oestradiol+SHBG 70.001 (0.13) 0.11 70.001 (0.19) 0.04 70.48 (0.13) 0.26 70.30 (0.39) 0.13
Oestradiol+SHBG+age+waist
c 70.001 (0.36) 0.53 70.001 (0.47) 0.33 70.14 (0.63) 0.48 70.10 (0.76) 0.22
SHBG (pmol ml
71) n=193, 188 0.30 (50.001) 0.10 0.02 (0.01) 0.04 0.05 (50.001) 0.25 0.04 (50.001) 0.12
SHBG+age+waist
c 0.004 (0.48) 0.53 70.003 (0.60) 0.33 0.02 (0.01) 0.48 0.02 (0.06) 0.22
Free eostradiol
f (%) 70.03 (50.001) 0.11 70.19 (0.002) 0.05 70.28 (50.001) 0.19 70.20 (50.001) 0.10
Free oestradiol+age+waist
c 70.04 (0.40) 0.53 0.01 (0.85) 0.33 70.09 (0.03) 0.47 70.09 (0.06) 0.22
Progesterone
e (nmol l
71) 0.18 (0.02) 0.03 0.09 (0.24) 0.01 1.17 (0.02) 0.03 1.00 (0.05) 0.02
Progesterone+age+waist
c 0.03 (0.56) 0.52 70.01 (0.85) 0.33 0.45 (0.24) 0.47 0.59 (0.20) 0.21
*Regression coefﬁcients shown are for each hormone and growth factor before and after adjusting for the other variables shown;
ainsulin-like growth factor;
binsulin-like growth
factor binding protein;
cinverse transformed;
dpower transformed;
esquare root transformed;
fsquare transformed;
gage and waist adjusted models also include a quadratic term
for age.
Table 3 Least square means of selected hormones by quintiles of %
dense: pre-menopausal women*
% IGF-1 IGFBP-3 Ratio
A Dense (ng ml
71) (mg ml
71)( mgm l
71)
Quintiles Median LS mean LS mean LS mean
1 1.5 149.36 2.80 55.39
2 8.4 142.89 2.63 54.53
3 26.70 158.60 2.66 59.41
4 42.50 163.60 2.60 62.06
5 61.0 158.67 2.78 58.72
Post-menopausal women
% Prolactin SHBG Free oestradiol
B Dense (mgm l
71) (pmol ml
1) (%)
Quintiles median LS mean LS mean LS mean
1 0.7 7.43 36.83 2.37
2 5.7 8.35 39.61 1.97
3 19.70 9.27 40.54 1.75
4 34.70 11.17 45.25 1.85
5 52.90 11.52 51.93 1.84
*These tables are for descriptive purposes only. Untransformed least square means
of growth factor and hormones are given for quintiles of per cent density. Least
square means are generated from simple linear regressions controlling for age and
waist (inverse transformed) for pre-menopausal models and age, waist (inverse trans-
formed) and an additional quadratic term for age for the post-menopausal models.
The IGF-1 model also controls for IGFBP-3.
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cent density=52.9%), relative to the ﬁrst (median per cent
density=0.7%). Also in the postmenopausal, SHBG levels were
29% higher in the ﬁfth quintile, and calculated free oestradiol levels
were 22% lower in the ﬁfth quintile of per cent density compared
to the ﬁrst.
DISCUSSION
The proportion of the mammogram occupied by radiologically
dense tissue reﬂects the proportion of the breast that is comprised
of epithelium and/or stroma, and is strongly related to risk of
breast cancer (Boyd et al, 1998). These results show that four
factors that have effects on cell proliferation in the breast are asso-
ciated with variations in mammographic densities. Before
adjustment for other risk factors, IGF-I and growth hormone, both
mitogens in the breast (Yee, 1998), were both positively associated
with per cent mammographic density in premenopausal women,
and IGFBP-3, an inhibitor of cell proliferation that also promotes
apoptosis (Yee et al, 1991), was negatively associated with density.
In postmenopausal women, IGF-I, growth hormone and prolactin,
also a mitogen (Friesen, 1976), were associated positively with per
cent density. After adjustment for the waist measurement, only
IGF-I in the premenopausal, and prolactin in the postmenopausal,
remained signiﬁcantly associated with per cent density. After
adjustment, total oestradiol was not signiﬁcantly associated with
mammographic density in either menopausal group. Although a
larger study would have greater statistical power to detect associa-
tions, those seen here between mammographic density and total
oestradiol were negative in direction. In postmenopausal women,
per cent density was strongly and positively associated with SHBG,
and was negatively associated with free oestradiol. Blood levels of
SHBG explained more variance in per cent mammographic density
than any of the other hormones or growth factors measured here.
The time interval between the mammogram and blood collec-
tion was relatively short, an average of 5 months, and blood
levels of progesterone conﬁrmed that blood collection was carried
out in the luteal phase of the menstrual cycle in more than 80% of
premenopausal women, but the phase of the cycle at the time of
the mammogram was not known. However, the coefﬁcient of
variation for per cent density was the same in premenopausal
and postmenopausal subjects (respectively 79.2 and 87.6), suggest-
ing that, after allowance has been made for the difference in mean
level, the menstrual cycle was not a major source of variation in
per cent density in premenopausal subjects.
These results in part conﬁrm the ﬁndings of a cross-sectional
study in the Nurses Health Study (NHS) by Byrne et al (2000)
which showed that blood levels of IGF-I were correlated positively,
and IGFBP-3 negatively, with per cent mammographic density in
premenopausal but not in postmenopausal women. We have found
in previous work, using immunohistochemistry in breast biopsies,
that the area of tissue stained for IGF-I is associated with mammo-
graphic density in women under the age of 50, but not in older
women (Guo et al, 2001). It has also been shown in a cohort study,
carried out in the NHS, that higher blood levels of IGF-I were
related to the subsequent development of breast cancer in preme-
nopausal but not postmenopausal women (Hankinson et al, 1998).
A further study in the NHS found higher blood levels of prolactin
to be associated with an increased risk of breast cancer in postme-
nopausal, but not in premenopausal women (Hankinson et al,
1999).
The associations of IGF-I and prolactin with risk of breast
cancer in the NHS, respectively in pre and postmenopausal
women, are thus similar to the associations with mammographic
densities according to menopausal status seen in the present study.
The average age of the premenopausal women studied here was 45
years, and some may have been perimenopausal. The association of
growth factors and hormones at earlier ages is at present unknown
but it is known that blood levels of IGF-I peak in adolescence
(Massa et al, 1992; Cara et al, 1987), and that mammographic
density is also greatest in early life (Hart et al, 1989).
Because of the known biological activities of IGF-I, growth
hormone and prolactin, and their associations with breast cancer
in humans and/or animal systems, these data suggest potential
biological mechanisms for the association of mammographic densi-
ties with risk of breast cancer. There is increasing evidence that the
growth hormone-IGF-I axis plays a role in carcinogenesis in the
breast (Pollak, 1998; Ruan et al, 1992) and transgenic mice that
over-express IGF-I or growth hormone have an increased incidence
of mammary cancer (Tornell et al, 1992; Macaulay, 1992; Ruan et
al, 1992; Yee, 1998). The administration of growth hormone to
ageing female monkeys induced hyperplasia of the mammary
epithelium, with a striking increase in the number and cellularity
of lobules, and an increase in the mitotic labelling index (Ng et
al, 1997). Further, similar factors inﬂuence mammographic densi-
ties, and the hormones and growth factors found here to be
associated with them. Breast density decreases with increasing
age, after pregnancy, and at the menopause (Brisson et al, 1982;
de Waard et al, 1984; Grove et al, 1985; Byrne et al, 1995). Blood
levels of growth hormone, IGF-I and prolactin also decline with
increasing age (Hall et al, 1999). Prolactin levels are also perma-
nently reduced by pregnancy, and are lower after the menopause
than before (Reyes et al, 1977; Wang et al, 1988; Metka et al,
1995; Nasu et al, 1997).
However, in contrast to the lack of association between total
oestradiol and mammographic densities observed here, higher
blood levels of total oestradiol have been found in postmenopausal
women to be associated with an increased risk of breast cancer
(Toniolo et al, 1995; Cauley et al, 1999). Further, oestrogen repla-
cement therapy (ERT) increases breast density in some subjects,
particularly when combined with a progestin (Rutter et al, 2001),
and Tamoxifen has been shown to decrease mammographic densi-
ties (Atkinson et al, 1999; Brisson et al, 2000; Chow et al, 2000).
However, these agents also affect the growth hormone-IGF-I axis.
ERT increases blood levels of growth hormone, and reduces blood
levels of IGF-I (Andersen et al, 1980), and Tamoxifen reduces
secretion of growth hormone (Malaab et al, 1992), and lowers
blood levels of IGF-I, at least in postmenopausal women (Pollak
et al, 1990).
Mammographic densities in postmenopausal women were
surprisingly associated positively with serum SHBG levels, and
negatively with serum free oestradiol levels. These data imply that
any oestrogenic effects on breast density are not related to the non-
protein bound or ‘free’ fraction of oestradiol in the circulation,
that is generally considered to be the biologically active form. It
is possible therefore that SHBG itself may help to promote the
effects of oestradiol in more direct ways, for instance by interacting
with plasma membrane binding sites in target cells within the
breast (Fortunati et al, 1999).
It is uncertain whether the associations found here between
mammographic densities and blood levels of IGF-I, prolactin
and SHBG are the result of one, or more than one, underlying
mechanism(s). Some of the observed features may be explained
by the actions of growth hormone. IGF-I is produced in the liver
and other tissues, including the breast, in response to growth
hormone (Herington, 1991), and blood levels of both IGF-I and
prolactin are elevated in transgenic mice that over-express growth
hormone (Bartke et al, 1999). Blood levels of SHBG could be
inﬂuenced indirectly by growth hormone, through their common
association with body fat stores, which are in part regulated by
growth hormone (Wabitsch et al, 1995; Ng et al, 1997; Considine,
1997), and are negatively correlated with SHBG (Plymate et al,
1990) The strong negative associations observed in these data
between the mammographic measures of per cent density and
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rate biological effects of growth hormone respectively on the
proliferation of breast tissue, and on the mobilisation of fat
stores.
An alternative potential explanation for these ﬁndings may lie in
the known actions of oestrogen. Oestrogen is involved in the
control of the secretion of both growth hormone (Malaab et al,
1992; Veldhuis, 1996; Veldhuis et al, 2001) and prolactin (Yen et
al, 1974; Adashi et al, 1980; Gudelsky et al, 1981), and regulates
the synthesis and blood levels of SHBG (Loukovaara et al, 1995;
Pasquali et al, 1997). Although blood levels of oestradiol were
not positively associated with mammographic density in the
present study, other forms of oestrogen not measured here, includ-
ing oestrogen metabolites, might be responsible for the observed
ﬁndings.
These ﬁndings suggest novel potential approaches to breast
cancer prevention, directed at modulation of the growth
hormone-IGF-I axis and prolactin. Furthermore, unexpected rela-
tionships between the determinants of serum free oestradiol
levels and mammographic densities suggest that manipulation of
SHBG levels or function could also be beneﬁcial. There is clearly
a need for an improved understanding of the genetic and environ-
mental factors that inﬂuence levels of these hormones and growth
factors, and in particular the relationship between these factors and
other known inﬂuences on risk of breast cancer, including familial,
menstrual and reproductive risk factors, and ovarian hormones.
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